PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage regenerative medicine company focused on cell therapy treatments for chronic kidney disease. The company reached public markets through a merger with SCS Capital Acquisition Corp., a blank-check vehicle that completed its initial public offering in 2021 with SCS Capital LLC serving as sponsor; the business combination closed in 2022. On March 31, 2025, ProKidney filed a Form S-4 registration statement with the Securities and Exchange Commission, indicating a pending transaction requiring registered securities. The company operates within the biotechnology and cell therapy sector. Visit SpacDesk and create a free account to access complete filing data, transaction timelines, and ongoing coverage of PROK and the broader SPAC universe.